SC 13G 1 a67728sc13g.txt SCHEDULE 13G 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. _)* Genelabs Technologies, Inc. ------------------------------------------------------- (NAME OF ISSUER) Common Stock, No Par Value ------------------------------------------------------- (TITLE OF CLASS OF SECURITIES) 368706107 ------------------------------------------------------- (CUSIP NUMBER) Not Applicable ------------------------------------------------------- (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this page shall not be deemed to be "filed" for the purpose of Section18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 Cusip 368706107 Page 2 of 4 Pages 13G -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSONS S.S. OR IRS IDENTIFICATION NO. OF ABOVE PERSON Watson Pharmaceuticals, Inc. 95-3872914 -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ___ Not Applicable (b) ___ -------------------------------------------------------------------------------- 3 SEC USE ONLY -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION a Nevada corporation -------------------------------------------------------------------------------- 5 SOLE VOTING POWER NUMBER OF 3,500,000(1) SHARES ------------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER OWNED BY -0- EACH ------------------------------------------------------- 7 SOLE DISPOSITIVE POWER REPORTING 3,500,000(1) PERSON ------------------------------------------------------- WITH 8 SHARED DISPOSITIVE POWER -0- -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,500,000(1) -------------------------------------------------------------------------------- 10 CHECK THE BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES * Not Applicable -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 7.6% -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON* CO -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILING (1) Includes 500,000 shares of Common Stock issuable upon exercise of warrants. 3 Cusip 368706107 Page 3 of 4 Pages Item 1(a) - Name of Issuer: Genelabs Technologies, Inc. Item 1(b) - Address of Issuer's Principal Executive Offices: 505 Penobscot Drive Redwood City, CA 94063-4738 Item 2(a) - Name of Person Filing: Watson Pharmaceuticals, Inc. Item 2(b) - Address of Principal Business Office: 311 Bonnie Circle Corona, CA 92880 Item 2(c) - Citizenship: Nevada, USA (Place of Incorporation) Item 2(d) - Title of Class of Securities: Common Stock Item 2(e) - Cusip Number: 368706107 Item 3 - This statement is being filed pursuant to Rule 13d-1(c). Item 4(a) - Amount beneficially owned: 3,500,000(1) Item 4(b) - Percent of Class: 7.6% Item 4(c) - Number of Shares to which Watson has: (i) sole power to vote or to direct the vote: 3,500,000(1) (ii) shared power to vote or to direct the vote: -0- (iii) sole power to dispose or to direct the disposition of: 3,500,000(1) (iv) shared power to dispose or to direct the disposition of: -0- Item 5 - Ownership of Five Percent or Less of a Class: Not Applicable Item 6 - Ownership of More than Five percent on Behalf of Another Person: Not applicable Item 7 - Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company: Not Applicable Item 8 - Identification and Classification of Members of the Group: Not Applicable ---------- (1) Includes 500,000 shares of Common Stock issuable upon exercise of warrants. 4 Cusip 368706107 Page 4 of 4 Pages Item 9 - Notice of Dissolution of Group: Not Applicable Item 10 - Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: December 1, 2000 WATSON PHARMACEUTICALS, INC. By: /s/ Robert C. Funsten -------------------------------------- Robert C. Funsten Senior Vice President, General Counsel and Secretary